{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:21Z","timestamp":1791999441378,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013316","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000}}],"reference-count":317,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013316.pub2","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T11:26:01Z","timestamp":1615548361000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prognostic value of test(s) for O6-methylguanine\u2013DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide"],"prefix":"10.1002","volume":"2021","author":[{"given":"Alexandra","family":"McAleenan","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Kelly","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spiga","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Kernohan","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yuan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dawson","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"},{"name":"NIHR Applied Research Collaboration West (ARC West) ; University Hospitals Bristol and Weston NHS Foundation Trust; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomos","family":"Robinson","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Brandner","sequence":"additional","affiliation":[{"name":"Department of Neurodegenerative Disease; UCL Queen Square Institute of Neurology; London UK"},{"name":"Division of Neuropathology; The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L","family":"Faulkner","sequence":"additional","affiliation":[{"name":"Bristol Genetics Laboratory, Pathology Sciences; Southmead Hospital; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Wragg","sequence":"additional","affiliation":[{"name":"Bristol Genetics Laboratory, Pathology Sciences; Southmead Hospital; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jefferies","sequence":"additional","affiliation":[{"name":"Department of Oncology; Addenbrooke's Hospital; Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Howell","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Vale","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P T","family":"Higgins","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"},{"name":"NIHR Applied Research Collaboration West (ARC West) ; University Hospitals Bristol and Weston NHS Foundation Trust; Bristol UK"},{"name":"NIHR Bristol Biomedical Research Centre; University Hospitals Bristol and Weston NHS Foundation Trust; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathreena M","family":"Kurian","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"},{"name":"Bristol Medical School: Brain Tumour Research Centre, Public Health Sciences; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD013316.pub2-BIB0001|cit1","first-page":"655","article-title":"MGMT promoter methylation status in glioblastoma: a single institutional experience","volume":"98","author":"Almuqate","year":"2018","journal-title":"Laboratory Investigation"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00401-012-1016-2","article-title":"MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. [Erratum appears in Acta Neuropathologica 2013;126(1):159]","volume":"124","author":"Bady","year":"2012","journal-title":"Acta Neuropathologica"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/1471-2164-11-701","article-title":"DNA methylation in glioblastoma: impact on gene expression and clinical outcome","volume":"11","author":"Etcheverry","year":"2010","journal-title":"BMC Genomics"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00401-012-1016-2","article-title":"MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. [Erratum appears in Acta Neuropathologica 2013;126(1):159]","volume":"124","author":"Bady","year":"2012","journal-title":"Acta Neuropathologica"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD013316.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1158\/1538-7445.AM2012-4031","article-title":"MGMT methylation based outcome prediction is associated with two CpG regions separated by a prediction minimum centred at the initiation start site","volume":"72","author":"Bady","year":"2012","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013316.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/annonc\/mdv272","article-title":"Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer","volume":"26","author":"Barault","year":"2015","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2014.9.FOCUS14502","article-title":"Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles","volume":"37","author":"Barbagallo","year":"2014","journal-title":"Neurosurgical Focus"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamaoncol.2016.6020","article-title":"Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG Oncology RTOG 0525","volume":"3","author":"Bell","year":"2017","journal-title":"JAMA Oncology"},{"issue":"32","key":"10.1002\/14651858.CD013316.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11060-016-2116-y","article-title":"Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma","volume":"128","author":"Brigliadori","year":"2016","journal-title":"Journal of Neuro-oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013316.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.2015.33.15_suppl.2017","article-title":"Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity","volume":"33","author":"Rocca","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cns.13040","article-title":"Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas","volume":"25","author":"Chai","year":"2018","journal-title":"CNS Neuroscience and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cns.13040","article-title":"Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas","volume":"25","author":"Chai","year":"2018","journal-title":"CNS Neuroscience and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/nan.12415","article-title":"Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis","volume":"44","author":"Dahlrot","year":"2018","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0017|cit17","first-page":"334","article-title":"What is the clinical value of cancer stem cell markers in gliomas?","volume":"6","author":"Dahlrot","year":"2013","journal-title":"International Journal of Clinical & Experimental Pathology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/nan.12415","article-title":"Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis","volume":"44","author":"Dahlrot","year":"2018","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/sj.bjc.6605127","article-title":"Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy","volume":"101","author":"Dunn","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD013316.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1158\/1078-0432.CCR-08-2801","article-title":"Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients","volume":"15","author":"Felsberg","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-10-36","article-title":"MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR","volume":"10","author":"Havik","year":"2012","journal-title":"Journal of Translational Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.21873\/cgp.20102","article-title":"MGMT gene promoter methylation status \u2013 assessment of two pyrosequencing kits and three methylation-specific PCR methods for their predictive capacity in glioblastomas","volume":"15","author":"Johannessen","year":"2018","journal-title":"Cancer Genomics & Proteomics"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-014-1701-1","article-title":"Prognosis of glioblastoma with faint MGMT methylation-specific PCR product","volume":"122","author":"Hsu","year":"2015","journal-title":"Journal of Neuro-oncology"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/PAI.0000000000000331","article-title":"Comparative assessment of 4 methods to analyze MGMT status in a series of 121 glioblastoma patients","volume":"25","author":"Hsu","year":"2017","journal-title":"Applied Immunohistochemistry & Molecular Morphology"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e0186430","DOI":"10.1371\/journal.pone.0186430","article-title":"The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma","volume":"12","author":"Hsu","year":"2017","journal-title":"PloS One"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/PAS.0b013e318267b061","article-title":"Exclusion of histiocytes\/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma","volume":"37","author":"Hsu","year":"2013","journal-title":"American Journal of Surgical Pathology"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"e0179366","DOI":"10.1371\/journal.pone.0179366","article-title":"Detection of human cytomegalovirus in glioblastoma among Taiwanese subjects","volume":"12","author":"Yang","year":"2017","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11060-009-0031-1","article-title":"Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods","volume":"97","author":"Karayan-Tapon","year":"2010","journal-title":"Journal of Neuro-oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013316.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/S0959-8049(11)70914-5","article-title":"MGMT gene promoter methylation analysis by pyrosequencing of glial tumours","volume":"47","author":"Kim","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3340\/jkns.2016.59.1.26","article-title":"Prognostic role of methylation status of the MGMT promoter determined quantitatively by pyrosequencing in glioblastoma patients","volume":"59","author":"Kim","year":"2016","journal-title":"Journal of Korean Neurosurgical Society"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013316.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/neuonc\/nov222.14","article-title":"Prognostic role of methylation status of MGMT promoter on glioblastoma patients estimated quantitatively by pyrosequencing","volume":"17","author":"Kim","year":"2015","journal-title":"Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jnen\/nlv024","article-title":"Assessment of quantitative and allelic MGMT methylation patterns as a prognostic marker in glioblastoma","volume":"75","author":"Kristensen","year":"2016","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013316.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1200\/jco.2011.29.15_suppl.2003","article-title":"Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation","volume":"29","author":"Lai","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/neuonc\/nos308","article-title":"Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome","volume":"15","author":"Lalezari","year":"2013","journal-title":"Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.5301\/jbm.5000126","article-title":"MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens","volume":"30","author":"Lattanzio","year":"2015","journal-title":"International Journal of Biological Markers"},{"issue":"18","key":"10.1002\/14651858.CD013316.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1002\/cncr.27441","article-title":"O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide","volume":"118","author":"Lechapt-Zalcman","year":"2012","journal-title":"Cancer"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013316.pub2-BIB0037|cit37","first-page":"iii8","article-title":"The t genotype of the MGMT C > T (rs16906252) enhancer SNP is associated with promoter methylation and longer survival in patients with glioblastoma","volume":"14","author":"McDonald","year":"2012","journal-title":"Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejca.2012.08.012","article-title":"The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients","volume":"49","author":"McDonald","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013316.pub2-BIB0039|cit39","first-page":"S794","article-title":"MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy","volume":"49","author":"Gonzalez-Astorga","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1479-5876-10-250","article-title":"MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy","volume":"10","author":"Melguizo","year":"2012","journal-title":"Journal of Translational Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2174\/1568009615666150629130139","article-title":"An innovative fluorescent semi-quantitative methylation-specific PCR method for the determination of MGMT promoter methylation is reflecting intra-tumor heterogeneity","volume":"15","author":"Nguyen","year":"2015","journal-title":"Current Cancer Drug Targets"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/noq162","article-title":"Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients","volume":"13","author":"Park","year":"2011","journal-title":"Neuro-oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013316.pub2-BIB0043|cit43","first-page":"iii4","article-title":"Comparison of MS-PCR, MethyLight, pyrosequencing, MS-HRM, and immunohistochemistry for MGMT analysis","volume":"12","author":"Quillien","year":"2010","journal-title":"Neuro-oncology"},{"issue":"17","key":"10.1002\/14651858.CD013316.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1002\/cncr.27392","article-title":"Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients","volume":"118","author":"Quillien","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11060-013-1332-y","article-title":"Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients","volume":"116","author":"Quillien","year":"2014","journal-title":"Journal of Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11060-013-1332-y","article-title":"Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients","volume":"116","author":"Quillien","year":"2014","journal-title":"Journal of Neuro-oncology"},{"issue":"38","key":"10.1002\/14651858.CD013316.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"61916","DOI":"10.18632\/oncotarget.11322","article-title":"Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial","volume":"7","author":"Quillien","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/CBM-170191","article-title":"Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients","volume":"20","author":"Quillien","year":"2017","journal-title":"Cancer Biomarkers: Section A of Disease Markers"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/jnnp.2010.214593","article-title":"Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide","volume":"82","author":"Thon","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0050|cit50","first-page":"623","article-title":"Prognostic relevance of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from glioblastomas after primary concomitant radiochemotherapy followed by adjuvant temozolomide","volume":"50","author":"Thon","year":"2009","journal-title":"Proceedings of the American Association for Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0051|cit51","first-page":"865","article-title":"Prognostic relevance of MGMT promoter methylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas after primary radio-\/radiochemotherapy","volume":"10","author":"Thon","year":"2008","journal-title":"Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00415-016-8355-1","article-title":"Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference","volume":"264","author":"Thon","year":"2017","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3171\/2017.11.JNS171710","article-title":"MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?","volume":"130","author":"Yamashita","year":"2018","journal-title":"Journal of Neurosurgery"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013316.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/neuonc\/nox168.405","article-title":"Detection of MGMT promoter methylation levels with MS-HRM in patients with glioblastoma","volume":"19","author":"Yamashita","year":"2017","journal-title":"Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11060-011-0668-4","article-title":"O6-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas","volume":"106","author":"Yang","year":"2012","journal-title":"Journal of Neuro-oncology"},{"issue":"45","key":"10.1002\/14651858.CD013316.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"27728","DOI":"10.18632\/oncotarget.25543","article-title":"Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma","volume":"9","author":"Yoshioka","year":"2018","journal-title":"Oncotarget"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013316.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"vi117","DOI":"10.1093\/neuonc\/now212.487","article-title":"Comprehensive survival analysis of MGMT protein expression by traditional and quantitative fluorescence immunohistochemistry compared to MGMT promoter methylation in a large institutional glioblastoma cohort treated with the stupp protocol","volume":"18","author":"Becker","year":"2016","journal-title":"Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ijrobp.2018.06.093","article-title":"MGMT protein expression adds prognostic value beyond MGMT promoter methylation and stratifies survival prognoses of un-methylated glioblastoma patients","volume":"102","author":"Becker","year":"2018","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e33449","DOI":"10.1371\/journal.pone.0033449","article-title":"Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma","volume":"7","author":"Christians","year":"2012","journal-title":"PloS One"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013316.pub2-BIB0060|cit60","first-page":"iii142","article-title":"A retrospective review of the influence of quantitative MGMT methylation on survival after chemoradiotherapy for patients with glioblastoma","volume":"15","author":"Crosby","year":"2013","journal-title":"Neuro-oncology"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2217\/fon-2017-0437","article-title":"MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme","volume":"14","author":"Gurrieri","year":"2018","journal-title":"Future Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3892\/or_00000760","article-title":"Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma","volume":"23","author":"Jung","year":"2010","journal-title":"Oncology Reports"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-010-0267-9","article-title":"O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications","volume":"101","author":"Kang","year":"2011","journal-title":"Journal of Neuro-oncology"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1227\/01.NEU.0000357325.90347.A1","article-title":"The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas","volume":"65","author":"Cao","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0065|cit65","first-page":"7","article-title":"Clinical and cytogenetic factors of prognosis in glial tumors of the brain","volume":"4","author":"Dreval","year":"2009","journal-title":"Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuroimage.2011.09.076","article-title":"Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas","volume":"59","author":"Ellingson","year":"2012","journal-title":"Neuroimage"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e0178693","DOI":"10.1371\/journal.pone.0178693","article-title":"APNG as a prognostic marker in patients with glioblastoma","volume":"12","author":"Fosmark","year":"2017","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0068|cit68","first-page":"185","article-title":"Long-term survival of patients with glioblastoma multiforme treated with chemoradiation: correlation with MGMT promoter methylation status","volume":"186","author":"Grabenbauer","year":"2010","journal-title":"Strahlentherapie und Onkologie"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0069|cit69","first-page":"56","article-title":"Comparison of MGMT and ERCC2 expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship","volume":"91","author":"Hou","year":"2011","journal-title":"Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]"},{"issue":"11","key":"10.1002\/14651858.CD013316.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/1078-0432.CCR-11-3091","article-title":"MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma","volume":"18","author":"Jarboe","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.gene.2014.10.027","article-title":"IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme","volume":"554","author":"Kalkan","year":"2015","journal-title":"Gene"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0072|cit72","first-page":"129","article-title":"Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma","volume":"40","author":"Kamoshima","year":"2012","journal-title":"No Shinkei Geka [Neurological Surgery]"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0073|cit73","first-page":"437","article-title":"The impact of non-pathological factors on TMZ treatment of cerebral glioma","volume":"8","author":"Lin","year":"2008","journal-title":"Chinese Journal of Contemporary Neurology and Neurosurgery"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0074|cit74","first-page":"403","article-title":"Analysis of prognostic factors for survival in elderly patients with glioma","volume":"43","author":"Liu","year":"2018","journal-title":"Zhong Nan da Xue Xue Bao. Yi Xue Ban [Journal of Central South University. Medical Sciences]"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"10","DOI":"10.17116\/patol201678410-19","article-title":"Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma","volume":"78","author":"Lobanova","year":"2016","journal-title":"Arkhiv Patologii"},{"issue":"13","key":"10.1002\/14651858.CD013316.pub2-BIB0076|cit76","first-page":"781","article-title":"Efficacy of salvage chemotherapy based on MGMT protein expression in patients with recurrent malignant gliomas: a report of 30 cases","volume":"38","author":"Shen","year":"2011","journal-title":"Chinese Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013316.pub2-BIB0077|cit77","first-page":"1052","article-title":"Relationship between the expression of O6-methylguanine-DNA methyltransferase in glioma and the survival time of patients","volume":"23","author":"Sun","year":"2004","journal-title":"Chinese Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s12032-011-9901-4","article-title":"Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients","volume":"29","author":"Tang","year":"2012","journal-title":"Medical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013316.pub2-BIB0079|cit79","first-page":"766","article-title":"Prognostic value of CDKN2A mRNA level in glioblastoma","volume":"27","author":"Yan","year":"2015","journal-title":"Cancer Research and Clinic"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0080|cit80","first-page":"232","article-title":"Nimotuzumab in combination with chemotherapy for patients with malignant gliomas","volume":"33","author":"Yang","year":"2011","journal-title":"Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13063-018-2659-7","article-title":"A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial","volume":"19","author":"Rapp","year":"2018","journal-title":"Trials"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.clineuro.2012.12.023","article-title":"A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival","volume":"115","author":"Abhinav","year":"2013","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12885-015-1545-x","article-title":"Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma","volume":"15","author":"Adeberg","year":"2015","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1002\/14651858.CD013316.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"34414","DOI":"10.18632\/oncotarget.5437","article-title":"The radiosensitivity index predicts for overall survival in glioblastoma","volume":"6","author":"Ahmed","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"vdaa082","DOI":"10.1093\/noajnl\/vdaa082","article-title":"Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Alnahhas","year":"2020","journal-title":"Neuro-oncology Advances"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neucir.2017.07.005","article-title":"Prognostic and predictive factors in high-grade gliomas. Experience at our institution","volume":"28","author":"Alonso","year":"2017","journal-title":"Neurocirugia (Asturias, Spain)"},{"issue":"7306","key":"10.1002\/14651858.CD013316.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.323.7306.224","article-title":"Systematic reviews of evaluations of prognostic variables","volume":"323","author":"Altman","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0088|cit88","unstructured":"Aluko P Graybill E Craig D Henderson C Drummond M Wilson ECF on behalf of the Campbell and Cochrane Economics Methods Group Chapter 20: Economic evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bpa.12018","article-title":"Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics","volume":"23","author":"Appin","year":"2013","journal-title":"Brain Pathology"},{"issue":"11","key":"10.1002\/14651858.CD013316.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00262-012-1261-1","article-title":"Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I\/II trial","volume":"61","author":"Ardon","year":"2012","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40478-016-0351-2","article-title":"A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas","volume":"4","author":"Arita","year":"2016","journal-title":"Acta Neuropathologica Communications"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00280-017-3405-7","article-title":"Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma","volume":"80","author":"Badruddoja","year":"2017","journal-title":"Cancer Chemotherapy & Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11060-016-2065-5","article-title":"Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial","volume":"127","author":"Balana","year":"2016","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Balana C Capellades J Pineda E Estival A Puig J Domenech S Pseudoprogression as an adverse event of glioblastoma therapy Cancer Medicine 2017 6 12 2858 66","DOI":"10.1002\/cam4.1242"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5414\/NP300904","article-title":"Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions","volume":"34","author":"Bienkowski","year":"2015","journal-title":"Clinical Neuropathology"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/neuonc\/noy017","article-title":"Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology\/Radiation Therapy Oncology Group database","volume":"20","author":"Blumenthal","year":"2018","journal-title":"Neuro-oncology"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/modpathol.2012.166","article-title":"Significance of complete 1p\/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution","volume":"26","author":"Boots-Sprenger","year":"2013","journal-title":"Modern Pathology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Brandes AA Franceschi E Tosoni A Blatt V Pession A Tallini G MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients Journal of Clinical Oncology 2008 26 13 2192 7","DOI":"10.1200\/JCO.2007.14.8163"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Brandes AA Franceschi E Tosoni A Benevento F Scopece L Mazzocchi V Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status Cancer 2009 115 15 3512 8","DOI":"10.1002\/cncr.24406"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/neuonc\/nop050","article-title":"O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications","volume":"12","author":"Brandes","year":"2010","journal-title":"Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0101|cit101","unstructured":"Brandes AA Franceschi E Ermani M Tosoni A Albani F Depenni R Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center? Neuro-oncology Practice 2014 1 4 166 71"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Brandes AA Franceschi E Paccapelo A Tallini G De B Ghimenton C Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications Oncologist 2017 22 4 432 7","DOI":"10.1634\/theoncologist.2016-0254"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/nan.12246","article-title":"Diagnostic, prognostic and predictive relevance of molecular markers in gliomas","volume":"41","author":"Brandner","year":"2015","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0104|cit104","unstructured":"Brennan CW Verhaak RG McKenna A Campos B Noushmehr H Salama SR The somatic genomic landscape of glioblastoma. [Erratum appears in Cell 2014;157(3):753] Cell 2013 155 2 462 77"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Burford A Little SE Jury A Popov S Laxton R Doey L Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma PloS One 2013 8 8 e71777","DOI":"10.1371\/journal.pone.0071777"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Burger MC Breuer S Cieplik HC Harter PN Franz K Bahr O Bevacizumab for patients with recurrent multifocal glioblastomas International Journal of Molecular Sciences 2017 18 11 2469","DOI":"10.3390\/ijms18112469"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6602321","article-title":"Years of life lost (YLL) from cancer is an important measure of population burden and should be considered when allocating research funds","volume":"92","author":"Burnet","year":"2005","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler","year":"2020","journal-title":"Trends in Cancer"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/neuonc\/nor130","article-title":"Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma","volume":"13","author":"Butowski","year":"2011","journal-title":"Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11060-017-2726-z","article-title":"Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study","volume":"137","author":"Capellades","year":"2018","journal-title":"Journal of Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11060-018-2910-9","article-title":"Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma","volume":"139","author":"Chakhoyan","year":"2018","journal-title":"Journal of Neuro-oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.humpath.2014.10.002","article-title":"Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma","volume":"46","author":"Chen","year":"2015","journal-title":"Human Pathology"},{"issue":"33","key":"10.1002\/14651858.CD013316.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"53392","DOI":"10.18632\/oncotarget.10534","article-title":"The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-014-1709-6","article-title":"HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation","volume":"122","author":"Cheng","year":"2015","journal-title":"Journal of Neuro-oncology"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2006.07.4807","article-title":"Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide","volume":"25","author":"Chinot","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1148\/radiol.2016151913","article-title":"Incremental prognostic value of ADC histogram analysis over MGMT promoter methylation status in patients with glioblastoma","volume":"281","author":"Choi","year":"2016","journal-title":"Radiology"},{"issue":"23","key":"10.1002\/14651858.CD013316.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1200\/JCO.2008.20.7944","article-title":"Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma","volume":"27","author":"Clarke","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"233","DOI":"10.23736\/S0390-5616.16.03284-7","article-title":"Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging","volume":"61","author":"Coburger","year":"2017","journal-title":"Journal of Neurosurgical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/neuonc\/nop007","article-title":"A multigene predictor of outcome in glioblastoma","volume":"12","author":"Colman","year":"2010","journal-title":"Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1748-717X-6-115","article-title":"Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?","volume":"6","author":"Combs","year":"2011","journal-title":"Radiation Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"djv041","DOI":"10.1093\/jnci\/djv041","article-title":"EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide","volume":"107","author":"Cominelli","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0122|cit122","first-page":"1655","article-title":"Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study","volume":"23","author":"Costa","year":"2010","journal-title":"Oncology Reports"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-006-9320-0","article-title":"MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities","volume":"83","author":"Criniere","year":"2007","journal-title":"Journal of Neuro-oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013316.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"vi182","DOI":"10.1093\/neuonc\/nox168.741","article-title":"Time-varying effect of MGMT methylation level on survival of glioblastoma multiforme","volume":"19","author":"Dahlrot","year":"2017","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jocn.2010.04.050","article-title":"A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival","volume":"18","author":"Das","year":"2011","journal-title":"Journal of Clinical Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jrsm.1266","article-title":"Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests","volume":"9","author":"Debray","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13277-015-4240-2","article-title":"MGMT testing allows for personalised therapy in the temozolomide era","volume":"37","author":"Dullea","year":"2016","journal-title":"Tumor Biology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0128|cit128","unstructured":"Engauge Digitizer Software Mitchell M Muftakhidinov B Winchen T van Schaik B Wilms A J\u0119drzejewski-Szmek Z Zenodo 2020 10.5281\/zenodo\/3941227"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0129|cit129","unstructured":"EPPI-Reviewer 4: software for research synthesis. EPPI-Centre Software Thomas J Brunton J Graziosi S Social Science Research Unit, UCL Institute of Education 2010"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0130|cit130","first-page":"793","article-title":"Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia","volume":"59","author":"Esteller","year":"1999","journal-title":"Cancer Research"},{"issue":"19","key":"10.1002\/14651858.CD013316.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013316.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"e104455","DOI":"10.1371\/journal.pone.0104455","article-title":"DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide","volume":"9","author":"Etcheverry","year":"2014","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11060-020-03607-4","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma","volume":"150","author":"Farrell","year":"2020","journal-title":"Journal of Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ijc.26083","article-title":"Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas","volume":"129","author":"Felsberg","year":"2011","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11060-014-1395-4","article-title":"MGMT promoter methylation in plasma of glioma patients receiving temozolomide","volume":"117","author":"Fiano","year":"2014","journal-title":"Journal of Neuro-oncology"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jnen\/nlw052","article-title":"MGMT-methylated alleles are distributed heterogeneously within glioma samples irrespective of IDH status and chromosome 10q deletion","volume":"75","author":"Fontana","year":"2016","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-016-2093-1","article-title":"Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study","volume":"128","author":"Franceschi","year":"2016","journal-title":"Journal of Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/j.wneu.2018.01.045","article-title":"The prognostic roles of gender and O6-Methylguanine-DNA methyltransferase methylation status in glioblastoma patients: the female power","volume":"112","author":"Franceschi","year":"2018","journal-title":"World Neurosurgery"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00259-014-2959-4","article-title":"Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET","volume":"42","author":"Galldiks","year":"2015","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"22","key":"10.1002\/14651858.CD013316.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1200\/JCO.2011.34.8086","article-title":"Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial","volume":"29","author":"Gallego Perez-Larraya","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"32","key":"10.1002\/14651858.CD013316.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0143|cit143","first-page":"669","article-title":"An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825","volume":"19","author":"Gittleman","year":"2017","journal-title":"Neuro-oncology"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1200\/JCO.2008.19.2195","article-title":"Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide","volume":"27","author":"Glas","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","article-title":"Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981\/CE.3","volume":"9","author":"Gorlia","year":"2008","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0146|cit146","unstructured":"Great Ormand Street Hospital for Children NHS Foundation Trust North East Thames Regional Genetics Service. Pricing 2018\/9 www.labs.gosh.nhs.uk\/media\/1390838\/nhs_joint_price_list_01.01.2019.pdf"},{"issue":"14","key":"10.1002\/14651858.CD013316.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.30023","article-title":"Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009","volume":"122","author":"Gramatzki","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3109\/02688697.2013.791664","article-title":"MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers","volume":"27","author":"Gutenberg","year":"2013","journal-title":"British Journal of Neurosurgery"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00701-012-1583-y","article-title":"Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis","volume":"155","author":"Gutenberg","year":"2013","journal-title":"Acta Neurochirurgica"},{"issue":"7650","key":"10.1002\/14651858.CD013316.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-013-1073-y","article-title":"Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age","volume":"112","author":"Ha","year":"2013","journal-title":"Journal of Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"e1279","DOI":"10.1038\/cddis.2014.245","article-title":"miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas","volume":"5","author":"Haemmig","year":"2014","journal-title":"Cell Death & Disease"},{"issue":"9","key":"10.1002\/14651858.CD013316.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/neuonc\/nou044","article-title":"Phase II trial of 7 days on\/7 days off temozolomide for recurrent high-grade glioma","volume":"16","author":"Han","year":"2014","journal-title":"Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12885-015-1629-7","article-title":"Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma","volume":"15","author":"Han","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12885-015-1125-0","article-title":"The prognostic role of preoperative serum albumin levels in glioblastoma patients","volume":"15","author":"Han","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-018-2786-8","article-title":"Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?","volume":"138","author":"Happold","year":"2018","journal-title":"Journal of Neuro-oncology"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.molonc.2014.11.004","article-title":"Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature","volume":"9","author":"Hayes","year":"2015","journal-title":"Molecular Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-03-0384","article-title":"Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide","volume":"10","author":"Hegi","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013316.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/neuonc\/nov198","article-title":"Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma?","volume":"17","author":"Hegi","year":"2015","journal-title":"Neuro-oncology"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-18-3181","article-title":"Promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials","volume":"25","author":"Hegi","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"27","key":"10.1002\/14651858.CD013316.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1200\/JCO.2006.06.9104","article-title":"Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03","volume":"24","author":"Herrlinger","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1200\/JCO.2008.19.2195","article-title":"Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide","volume":"27","author":"Herrlinger","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-08-2062","article-title":"Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation","volume":"15","author":"Hervouet","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD013316.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/PAS.0b013e3182518e12","article-title":"Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas","volume":"36","author":"Hobbs","year":"2012","journal-title":"American Journal of Surgical Pathology"},{"issue":"69","key":"10.1002\/14651858.CD013316.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"113766","DOI":"10.18632\/oncotarget.22667","article-title":"BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fonc.2018.00314","article-title":"Glioblastoma recurrence correlates with increased APE1 and polarization toward an immuno-suppressive microenvironment","volume":"8","author":"Hudson","year":"2018","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2046-4053-2-71","article-title":"Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework","volume":"2","author":"Huguet","year":"2013","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12967-017-1202-z","article-title":"A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients","volume":"15","author":"Inoges","year":"2017","journal-title":"Journal of Translational Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10014-015-0227-3","article-title":"Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma","volume":"32","author":"Ishida","year":"2015","journal-title":"Brain Tumor Pathology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3171\/2014.5.JNS132392","article-title":"Phase I\/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma","volume":"121","author":"Ishikawa","year":"2014","journal-title":"Journal of Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11940-018-0489-2","article-title":"Combining clinical and molecular data to predict the benefits of carmustine wafers in newly diagnosed high-grade gliomas","volume":"20","author":"Ius","year":"2018","journal-title":"Current Treatment Options in Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/neuros\/nyw026","article-title":"The pluripotent stem-cell marker alkaline phosphatase is highly expressed in refractory glioblastoma with DNA hypomethylation","volume":"80","author":"Iwadate","year":"2017","journal-title":"Neurosurgery"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3389\/fimmu.2018.00727","article-title":"Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme","volume":"9","author":"Jan","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0179|cit179","unstructured":"Neuro-oncology top 10 www.jla.nihr.ac.uk\/priority-setting-partnerships\/neuro-oncology\/top-10-priorities\/"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10330-011-0928-y","article-title":"Temozolomide and radiotherapy in newly diagnosed glioblastoma patients: O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status and Ki-67 as biomarkers for survival and response to treatment","volume":"11","author":"Karim","year":"2012","journal-title":"Chinese-German Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/neuonc\/nox160","article-title":"Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation","volume":"20","author":"Kessler","year":"2018","journal-title":"Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ijrobp.2011.12.086","article-title":"MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study","volume":"84","author":"Kim","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4143\/crt.2015.473","article-title":"Concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide for newly diagnosed glioblastoma patients: a retrospective multicenter observation study in Korea","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1016\/j.wneu.2018.10.151","article-title":"Apparent diffusion coefficient as a predictive biomarker for survival in patients with treatment-naive glioblastoma using quantitative multiparametric magnetic resonance profiling","volume":"122","author":"Kim","year":"2018","journal-title":"World Neurosurgery"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0185|cit185","first-page":"205","article-title":"The biomarker potential of MGMT protein in glioblastoma is improved by exclusion of non-tumor cells","volume":"33","author":"Klitkou","year":"2014","journal-title":"Clinical Neuropathology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0186|cit186","first-page":"99","article-title":"The biomarker potential of MGMT protein in glioblastoma is improved by exclusion of non-tumor cells","volume":"1","author":"Klitkou","year":"2014","journal-title":"Brain Pathology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0187|cit187","first-page":"ii47","article-title":"The biomarker potential of MGMT protein expression in glioblastoma is improved by exclusion of non-tumor cells","volume":"2","author":"Klitkou","year":"2014","journal-title":"Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3174\/ajnr.A2286","article-title":"Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status","volume":"32","author":"Kong","year":"2011","journal-title":"American Journal of Neuroradiology"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/annonc\/mdt388","article-title":"Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy","volume":"24","author":"Kreth","year":"2013","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1349-7006.2011.02092.x","article-title":"MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients","volume":"102","author":"Lakomy","year":"2011","journal-title":"Cancer Science"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/neuonc\/not125","article-title":"Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma","volume":"15","author":"Laxton","year":"2013","journal-title":"Neuro-oncology"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/jso.23249","article-title":"Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas","volume":"107","author":"Lee","year":"2013","journal-title":"Journal of Surgical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-017-0465-1","article-title":"The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas","volume":"5","author":"Lee","year":"2017","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clineuro.2016.10.004","article-title":"IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy","volume":"151","author":"Li","year":"2016","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"e0151815","DOI":"10.1371\/journal.pone.0151815","article-title":"Comparative analysis of matrix metalloproteinase family members reveals that MMP9 predicts survival and response to temozolomide in patients with primary glioblastoma","volume":"11","author":"Li","year":"2016","journal-title":"PloS One"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-015-1923-x","article-title":"Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)","volume":"125","author":"Lombardi","year":"2015","journal-title":"Journal of Neuro-oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013316.pub2-BIB0197|cit197","first-page":"iii76","article-title":"MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role","volume":"19","author":"Lombardi","year":"2017","journal-title":"Neuro-oncology"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathologica"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.2147\/OTT.S120854","article-title":"beta-Elemene treatment of glioblastoma: a single-center retrospective study","volume":"9","author":"Ma","year":"2016","journal-title":"OncoTargets and therapy"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2217\/cns-2017-0001","article-title":"Postprogression survival in patients with glioblastoma treated with concurrent chemoradiotherapy: a routine care cohort study","volume":"6","author":"Majewska","year":"2017","journal-title":"CNS Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013316.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1080\/0284186X.2017.1332780","article-title":"Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial","volume":"56","author":"Malmstr\u00f6m","year":"2017","journal-title":"Acta Oncologica"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1002\/ijc.23805","article-title":"Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme","volume":"123","author":"Martini","year":"2008","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3892\/ol.2015.2980","article-title":"Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation","volume":"9","author":"McDonald","year":"2015","journal-title":"Oncology Letters"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-011-1703-6","article-title":"Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution","volume":"18","author":"Metellus","year":"2011","journal-title":"Annals of Surgical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/neuonc\/now274","article-title":"Characteristics of H3 K27M-mutant gliomas in adults","volume":"19","author":"Meyronet","year":"2017","journal-title":"Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/1471-2407-13-402","article-title":"Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution","volume":"13","author":"Michaelsen","year":"2013","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11060-017-2739-7","article-title":"Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival","volume":"137","author":"Michaelsen","year":"2018","journal-title":"Journal of Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11060-010-0446-8","article-title":"Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma","volume":"103","author":"Minniti","year":"2011","journal-title":"Journal of Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11060-010-0324-4","article-title":"Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide","volume":"102","author":"Minniti","year":"2011","journal-title":"Journal of Neuro-oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2014.09.013","article-title":"Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis","volume":"91","author":"Minniti","year":"2015","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/neup.12091","article-title":"Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma","volume":"34","author":"Miyazaki","year":"2014","journal-title":"Neuropathology"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1593\/neo.111338","article-title":"Expression of EGFRvIII in glioblastoma: prognostic significance revisited","volume":"13","author":"Montano","year":"2011","journal-title":"Neoplasia (New York, N.Y.)"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2407-10-48","article-title":"Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference","volume":"10","author":"Morandi","year":"2010","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.25637","article-title":"Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter","volume":"117","author":"Motomura","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11060-015-1738-9","article-title":"Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients","volume":"122","author":"Mur","year":"2015","journal-title":"Journal of Neuro-oncology"},{"issue":"22","key":"10.1002\/14651858.CD013316.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1002\/cncr.27585","article-title":"A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)","volume":"118","author":"Nabors","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jjco\/hym132","article-title":"Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide","volume":"37","author":"Nagane","year":"2007","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0220|cit220","unstructured":"National Institute for Health and Care Excellence Appendices B\u2013I. The guidelines manual. Process and methods (PMG6), 2012 www.nice.org.uk\/process\/pmg6\/resources\/the-guidelines-manual-appendices-bi-2549703709\/"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0221|cit221","unstructured":"National Institute for Health and Care Excellence Brain tumours (primary) and brain metastases in adults. NICE guideline (NG99), 2018 www.nice.org.uk\/guidance\/ng99"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"e23332","DOI":"10.1371\/journal.pone.0023332","article-title":"The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma","volume":"6","author":"Ohka","year":"2011","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0223|cit223","first-page":"iii124","article-title":"Clinical and molecular characteristics of newly diagnosed glioblastomas with IDH1 mutation and correlation of IDH1 mutations with prognosis","volume":"3","author":"Ohno","year":"2013","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jjco\/hyv170","article-title":"Glioblastomas with IDH1\/2 mutations have a short clinical history and have a favorable clinical outcome","volume":"46","author":"Ohno","year":"2016","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"Olesen","year":"2012","journal-title":"European Journal of Neurology"},{"issue":"19","key":"10.1002\/14651858.CD013316.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1078-0432.CCR-14-0822","article-title":"Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma","volume":"20","author":"Omuro","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \"state of the science\" review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro-oncology"},{"issue":"24","key":"10.1002\/14651858.CD013316.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"8205","DOI":"10.1158\/1078-0432.CCR-08-0644","article-title":"Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme","volume":"14","author":"Pallini","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"vi107","DOI":"10.1093\/annonc\/mdw367.15","article-title":"MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role","volume":"27","author":"Pambuku","year":"2016","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11060-013-1060-3","article-title":"The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma","volume":"112","author":"Park","year":"2013","journal-title":"Journal of Neuro-oncology"},{"issue":"24","key":"10.1002\/14651858.CD013316.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3109\/00207454.2012.738735","article-title":"A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma","volume":"123","author":"Pei","year":"2013","journal-title":"International Journal of Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11060-017-2682-7","article-title":"Characteristics of cerebellar glioblastomas in adults","volume":"136","author":"Picart","year":"2018","journal-title":"Journal of Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00259-016-3494-2","article-title":"The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma","volume":"44","author":"Poulsen","year":"2017","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2008.18.9639","article-title":"Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma","volume":"27","author":"Prados","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tranon.2016.06.005","article-title":"Prognostic stratification of GBMs using combinatorial assessment of IDH1 mutation, MGMT promoter methylation, and TERT mutation status: experience from a tertiary care center in India","volume":"9","author":"Purkait","year":"2016","journal-title":"Translational Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1349-7006.2011.02134.x","article-title":"IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma","volume":"103","author":"Qi","year":"2012","journal-title":"Cancer Science"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11060-014-1372-y","article-title":"Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma","volume":"117","author":"Rankeillor","year":"2014","journal-title":"Journal of Neuro-oncology"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/neuonc\/nov064","article-title":"The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide","volume":"17","author":"Rapkins","year":"2015","journal-title":"Neuro-oncology"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/02688697.2013.767317","article-title":"The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma \u2013 a single centre retrospective study","volume":"27","author":"Rapp","year":"2013","journal-title":"British Journal of Neurosurgery"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ijc.27385","article-title":"Predictive impact of MGMT promoter methylation in glioblastoma of the elderly","volume":"131","author":"Reifenberger","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"27","key":"10.1002\/14651858.CD013316.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"e7422","DOI":"10.1097\/MD.0000000000007422","article-title":"Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: a single-center analysis","volume":"96","author":"Roh","year":"2017","journal-title":"Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00330-012-2601-4","article-title":"Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status","volume":"23","author":"Romano","year":"2013","journal-title":"European Radiology"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/neuonc\/nos338","article-title":"Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme","volume":"15","author":"Rosati","year":"2013","journal-title":"Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2018.10.003","article-title":"Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients","volume":"130","author":"Rosenschold","year":"2019","journal-title":"Radiotherapy and Oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0246|cit246","first-page":"S250","article-title":"Study of the methylation status of O-6-methylguanine-DNA methyltransferase in glioblastomas and related overall survival","volume":"Suppl 1","author":"Rubio Fernandez","year":"2014","journal-title":"Virchows Archiv"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2008.09.002","article-title":"MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma","volume":"45","author":"Sadones","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.wneu.2017.05.165","article-title":"High expression of glypican-1 predicts dissemination and poor prognosis in glioblastomas","volume":"105","author":"Saito","year":"2017","journal-title":"World Neurosurgery"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.wneu.2016.09.072","article-title":"Permeability surface area product using perfusion computed tomography is a valuable prognostic factor in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Saito","year":"2017","journal-title":"World Neurosurgery"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0250|cit250","first-page":"30","article-title":"Malignancy index using intraoperative flow cytometry is a valuable prognostic factor for glioblastoma treated with radiotherapy and concomitant temozolomide","volume":"30","author":"Saito","year":"2018","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10143-017-0903-3","article-title":"Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients","volume":"41","author":"Saito","year":"2018","journal-title":"Neurosurgical Review"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3171\/2016.11.JNS162326","article-title":"Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide","volume":"128","author":"Saito","year":"2018","journal-title":"Journal of Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3171\/2012.4.JNS101702","article-title":"Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients","volume":"117","author":"Salvati","year":"2012","journal-title":"Journal of Neurosurgery"},{"issue":"12","key":"10.1002\/14651858.CD013316.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1093\/carcin\/bgu212","article-title":"Risk score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients","volume":"35","author":"Sana","year":"2014","journal-title":"Carcinogenesis"},{"issue":"1-2","key":"10.1002\/14651858.CD013316.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jns.2014.10.043","article-title":"The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma multiforme clinical outcomes","volume":"347","author":"Saraiva-Esperon","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-018-2957-7","article-title":"Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors","volume":"140","author":"Sasaki","year":"2018","journal-title":"Journal of Neuro-oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/annonc\/mdn548","article-title":"A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients","volume":"20","author":"Schaich","year":"2009","journal-title":"Annals of Oncology"},{"issue":"34","key":"10.1002\/14651858.CD013316.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"55169","DOI":"10.18632\/oncotarget.10465","article-title":"Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma","volume":"7","author":"Schiffgens","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1541-7786.MCR-16-0322","article-title":"Prognostic relevance of tumor purity and interaction with MGMT methylation in glioblastoma","volume":"15","author":"Schulze Heuling","year":"2017","journal-title":"Molecular Cancer Research : MCR"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0260|cit260","unstructured":"Shemilt I The Campbell and Cochrane Economics Methods Group (CCEMG) and the Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre) CCEMG-EPPI-Centre cost converter, version 1.6 (updated April 2019) eppi.ioe.ac.uk\/costconversion\/"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1002\/cam4.1666","article-title":"The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival","volume":"7","author":"Shu","year":"2018","journal-title":"Cancer Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-008-9593-6","article-title":"Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme","volume":"89","author":"Sijben","year":"2008","journal-title":"Journal of Neuro-oncology"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1440-1789.2012.01297.x","article-title":"A study of clinico-pathological parameters and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma","volume":"32","author":"Singh","year":"2012","journal-title":"Neuropathology"},{"issue":"51","key":"10.1002\/14651858.CD013316.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21510","article-title":"Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation","volume":"21","author":"Snowsill","year":"2017","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00234-018-2060-y","article-title":"Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?","volume":"60","author":"Soike","year":"2018","journal-title":"Neuroradiology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1074\/mcp.M116.060657","article-title":"Protein markers predict survival in glioma patients","volume":"15","author":"Stetson","year":"2016","journal-title":"Molecular & Cellular Proteomics : MCP"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-012-0798-3","article-title":"Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery","volume":"108","author":"Stummer","year":"2012","journal-title":"Journal of Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncology"},{"issue":"16","key":"10.1002\/14651858.CD013316.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2009.26.6650","article-title":"Phase I\/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma","volume":"28","author":"Stupp","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0000000000001262","article-title":"Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM","volume":"84","author":"Suchorska","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013316.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3171\/2014.9.JNS14193","article-title":"Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma","volume":"122","author":"Sun","year":"2015","journal-title":"Journal of Neurosurgery"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3171\/2014.6.JNS132535","article-title":"Is the absolute value of O-6-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?","volume":"121","author":"Tanaka","year":"2014","journal-title":"Journal of Neurosurgery"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/jnnp.2010.214593","article-title":"Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide","volume":"82","author":"Thon","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0277|cit277","first-page":"4117","article-title":"Epidermal growth factor receptor expression may correlate with survival through clinical and radiological features of aggressiveness in glioblastoma treated with radiochemotherapy","volume":"35","author":"Tini","year":"2015","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clineuro.2016.07.023","article-title":"The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma","volume":"149","author":"Tini","year":"2016","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"9461402","DOI":"10.1155\/2017\/9461402","article-title":"Patients affected by unmethylated O(6)-methylguanine-DNA methyltransferase glioblastoma undergoing radiochemotherapy may benefit from moderately dose-escalated radiotherapy","volume":"2017","author":"Tini","year":"2017","journal-title":"BioMed Research International"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2018","journal-title":"Journal of Neuro-oncology"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12094-015-1381-0","article-title":"MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry","volume":"18","author":"Trabelsi","year":"2016","journal-title":"Clinical and Translational Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13039-017-0317-5","article-title":"Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy","volume":"10","author":"Urbschat","year":"2017","journal-title":"Molecular Cytogenetics"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3171\/2018.5.JNS18340","article-title":"Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma","volume":"131","author":"Dijken","year":"2019","journal-title":"Journal of Neurosurgery"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"604719","DOI":"10.1155\/2015\/604719","article-title":"The prognostic value of pyrosequencing-detected MGMT promoter hypermethylation in newly diagnosed patients with glioblastoma","volume":"2015","author":"Villani","year":"2015","journal-title":"Disease Markers"},{"issue":"24","key":"10.1002\/14651858.CD013316.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"10893","DOI":"10.7314\/APJCP.2014.15.24.10893","article-title":"Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation","volume":"15","author":"Wang","year":"2014","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12032-014-0363-3","article-title":"Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients","volume":"32","author":"Wang","year":"2015","journal-title":"Medical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/neuonc\/nov009","article-title":"Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525","volume":"17","author":"Wang","year":"2015","journal-title":"Neuro-oncology"},{"issue":"43","key":"10.1002\/14651858.CD013316.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"69991","DOI":"10.18632\/oncotarget.11726","article-title":"A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10014-011-0022-8","article-title":"O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma","volume":"28","author":"Watanabe","year":"2011","journal-title":"Brain Tumor Pathology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.radonc.2017.02.014","article-title":"Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: a multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status","volume":"123","author":"Wee","year":"2017","journal-title":"Radiotherapy and Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.radonc.2018.09.001","article-title":"Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: a multi-institutional collaborative study","volume":"129","author":"Wee","year":"2018","journal-title":"Radiotherapy and Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"e0178842","DOI":"10.1371\/journal.pone.0178842","article-title":"The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort","volume":"12","author":"Wei","year":"2017","journal-title":"PloS One"},{"issue":"34","key":"10.1002\/14651858.CD013316.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1200\/JCO.2009.23.0805","article-title":"Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network","volume":"27","author":"Weller","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013316.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","article-title":"MGMT promoter methylation Is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR Trial","volume":"21","author":"Weller","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD013316.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro-oncology"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD013316.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: a new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD013316.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"448","key":"10.1002\/14651858.CD013316.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1126\/scitranslmed.aar2238","article-title":"BCL3 expression promotes resistance to alkylating chemotherapy in gliomas","volume":"10","author":"Wu","year":"2018","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3171\/2016.1.JNS152153","article-title":"Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients","volume":"126","author":"Yan","year":"2017","journal-title":"Journal of Neurosurgery"},{"issue":"38","key":"10.1002\/14651858.CD013316.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"40896","DOI":"10.18632\/oncotarget.5683","article-title":"IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"52","key":"10.1002\/14651858.CD013316.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"89607","DOI":"10.18632\/oncotarget.19171","article-title":"Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas","volume":"8","author":"Yin","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/cns.12786","article-title":"A novel prognostic six-CpG signature in glioblastomas","volume":"24","author":"Yin","year":"2018","journal-title":"CNS Neuroscience and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD013316.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/neuonc\/not077","article-title":"Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma","volume":"15","author":"You","year":"2013","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jnci.2015.11.003","article-title":"Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant temozolomide","volume":"28","author":"Younis","year":"2016","journal-title":"Journal of Egyptian National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11060-017-2433-9","article-title":"Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients","volume":"133","author":"Yuan","year":"2017","journal-title":"Journal of Neuro-oncology"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3233\/CBM-170205","article-title":"A 4-miRNAs signature predicts survival in glioblastoma multiforme patients","volume":"20","author":"Yuan","year":"2017","journal-title":"Cancer Biomarkers: Section A of Disease Markers"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11060-013-1314-0","article-title":"The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma","volume":"116","author":"Yue","year":"2014","journal-title":"Journal of Neuro-oncology"},{"issue":"3","key":"10.1002\/14651858.CD013316.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10689-013-9607-1","article-title":"The prognostic value of MGMT promoter methylation in glioblastoma multiforme: a meta-analysis","volume":"12","author":"Zhang","year":"2013","journal-title":"Familial Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013316.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-013-1301-5","article-title":"Incidence and prognostic value of multiple gene promoter methylations in gliomas","volume":"116","author":"Zhang","year":"2014","journal-title":"Journal of Neuro-oncology"},{"key":"10.1002\/14651858.CD013316.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12957-016-1012-4","article-title":"The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis","volume":"14","author":"Zhao","year":"2016","journal-title":"World Journal of Surgical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013316.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PAT.0b013e328340bb26","article-title":"INI1 immunohistochemical expression in glioblastoma: correlation with MGMT gene promoter methylation status and patient survival","volume":"43","author":"Zunarelli","year":"2011","journal-title":"Pathology"},{"issue":"4","key":"10.1002\/14651858.CD013316.pub2-BIB0317|cit317","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013316","article-title":"Prognostic value of test(s) for O6-methylguanine\u2013DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide","author":"McAleenan","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T15:05:54Z","timestamp":1731596754000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013316.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":317,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013316.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]}}}